BaTeLab Co., Ltd.
HHKEX:214929.30
HKD
+0.54
(+1.88%)
BaTeLab Co., Ltd.
HKEX:2149
(Hong Kong Exchange)
Recent
price
29.30
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- BaTelab Co Ltd (2149.HK) is a biotechnology company focused on developing innovative testing solutions for the catering and food service industries. The company offers core products and services including saliva-based rapid test kits for COVID-19 detection, such as the Batelab® Saliva Antigen Rapid Test Kit; nucleic acid extraction systems like the Batelab® Viral Nucleic Acid Extraction Kit; and automated diagnostic platforms such as the Batelab® All-in-One Auto Nucleic Acid Extraction and Real-time PCR System, which enable high-throughput testing for pathogens including SARS-CoV-2, influenza, and respiratory syncytial virus; alongside customized OEM and ODM services for diagnostic reagents and instruments. These offerings cater primarily to healthcare providers, laboratories, and food service operators seeking efficient, non-invasive diagnostic tools. Founded in 2020 and headquartered in Hong Kong, BaTelab operates across Asia with distribution networks in mainland China, Southeast Asia, and expanding into international markets. The company targets B2B customers in the medical diagnostics and food safety sectors, emphasizing point-of-care testing solutions that reduce turnaround times and operational costs. In recent developments, BaTelab secured strategic partnerships with major diagnostic distributors in Southeast Asia in 2024 to broaden its market penetration; launched upgraded versions of its saliva test kits incorporating multiplex detection capabilities for multiple respiratory viruses in early 2025; and completed a funding round through its Hong Kong Stock Exchange listing in 2023, supporting R&D expansions into food pathogen testing kits. Additionally, the company reorganized its production facilities in 2024 to enhance capacity amid rising global demand for rapid diagnostics post-pandemic.